RT Journal Article
SR Electronic
T1 Evaluation of the Performance of Filmarray Blood Culture Identification Panel on Detecting Blood Cultures Containing Activated Carbon Powder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.05.21267325
DO 10.1101/2021.12.05.21267325
A1 Chen, Chen
A1 He, Shang
A1 Wang, Chengbin
YR 2021
UL http://medrxiv.org/content/early/2021/12/07/2021.12.05.21267325.abstract
AB Objective The FilmArray Blood Culture Identification (BCID) panel is a rapid microfluidic PCR amplification microbial detection system. Several studies have evaluated its clinical performance on the basis of blood culture bottles containing resins. However, proportion of hospitals in China use bottles with carbon power, which the performance of FilmArray has not been fully investigated. Therefore, this study is conducted to explore the accuracy of the panel using blood culture bottles with carbon power.Method 147 venous blood cultures containing carbon powder were used to assess the microbial and antibiotic resistance detection ability of the FilmArray panel. Outcomes were compared with results of the clinical combination method and their consistency was analyzed.Results FilmArray detected single microorganism in 121 samples, multiple microorganism in 9 cases and the consistency rate between the two methods was 90.6%. Among the 150 microorganisms detected, 85.1% (40/47) of staphylococcus contained the antibiotic resistant mecA gene, 15.3% (9/59) of Enterobacter detected the KPC gene, 7.7% (1/13) of Enterococcus has the vanA gene and the consistency with their clinical drug-resistant phenotypes were 93.6%, 86.4% and 100%, respectively.Conclusion The identification rate of the FilmArray BCID panel using venous blood cultures with activated carbon powder was highly consistent with the outcomes of previous researchers using non-carbon powder blood culture bottles. It is capable of providing rapid and reliable results in the detection of pathogens present in automated blood culture systems.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Biomedical Research Ethics Committee of the PLA General Hospital.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors